glp-1 liver fibrosis Why are agonists being used to treat patients with nonalcoholic fatty disease? Pioglitazone with SGLT2 inhibitors or

The pathogenesis originates from an imbalance in hepatic lipid homeostasis, where excessive triglyceride accumulation results from increased lipid influx, enhanced de novo lipogenesis, and impaired lipid export or oxidation

Table of Contents Understanding GLP-1 Therapy in Type 1 Diabetes Potential Benefits and Clinical Outcomes Risks, Safety Concerns, and Limitations Patient Selection and Practical Considerations Understanding GLP-1 Therapy in Type 1 Diabetes GLP-1 receptor agonists are well established in type 2 diabetes, yet their role in type 1 diabetes remains off-label

And then finally is autophagy, which is a self-repair, self-regenerative mechanism

Weight loss was more pronounced in patients with a BMI over 35, compared to those under 35

This risk seems to be highest in young people and women

Back La Barre J ((1932) 'Sur les possibilits d'un traitement du diabte par l'incrtine', Bulletin et memoires de l'Academie Royale de Mdecine de Belgique , 12, 62034